Four-year safety follow-up of the tetravalent dengue vaccine efficacy randomized controlled trials in Asia and Latin America

Capeding, 2014, Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial, Lancet, 384, 1358, 10.1016/S0140-6736(14)61060-6 Villar, 2015, Efficacy of a tetravalent dengue vaccine in children in Latin America, N Engl J Med, 372, 113, 10.1056/NEJMoa1411037 Guy, 2017, A recombinant live attenuated tetravalent vaccine for the prevention of dengue, Expert Rev Vaccines, 16, 1, 10.1080/14760584.2017.1335201 Gailhardou, 2016, Safety overview of a recombinant live-attenuated tetravalent dengue vaccine: pooled analysis of data from 18 clinical trials, PLoS Negl Trop Dis, 10, e0004821, 10.1371/journal.pntd.0004821 World Health Organization, 2008 Sabchareon, 2012, Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial, Lancet, 380, 1559, 10.1016/S0140-6736(12)61428-7 Hadinegoro, 2015, Efficacy and long-term safety of a dengue vaccine in regions of endemic disease, N Engl J Med, 373, 1195, 10.1056/NEJMoa1506223 World Health Organization, 2016, Dengue vaccine: WHO position paper – July 2016, Wkly Epidemiol Rec, 30, 349 Timiryasova, 2013, Optimization and validation of a plaque reduction neutralization test for the detection of neutralizing antibodies to four serotypes of dengue virus used in support of dengue vaccine development, Am J Trop Med Hyg, 88, 962, 10.4269/ajtmh.12-0461 Breslow, 1987, Statistical methods in cancer research. Volume II—the design and analysis of cohort studies, IARC Sci Publ, II, 1 Guy, 2016, Dengue vaccine: hypotheses to understand CYD-TDV-induced protection, Nat Rev Microbiol, 14, 45, 10.1038/nrmicro.2015.2 Mizumoto, 2014, On the risk of severe dengue during secondary infection: a systematic review coupled with mathematical modeling, J Vector Borne Dis, 51, 153 Cucunawangsih, 2017, Trends of dengue disease epidemiology, Virol Res Treat, 8 Ramos-Castaneda, 2017, Dengue in Latin America: systematic review of molecular epidemiological trends, PLoS Negl Trop Dis, 11, e0005224, 10.1371/journal.pntd.0005224 Acosta, 2016, Paradoxical role of antibodies in dengue virus infections: considerations for prophylactic vaccine development, Expert Rev Vaccines, 15, 467, 10.1586/14760584.2016.1121814 Harenberg, 2016, Cytokine profile of children hospitalized with virologically-confirmed dengue during two phase iii vaccine efficacy trials, PLoS Negl Trop Dis, 10, e0004830, 10.1371/journal.pntd.0004830 Guy, 2017, Which dengue vaccine approach is the most promising, and should we be concerned about enhanced disease after vaccination? Questions raised by the development and implementation of dengue vaccines: example of the Sanofi Pasteur tetravalent dengue vaccine, Cold Spring Harbor Persp Biol